Breast (Edinburgh, Scotland)

2025

Clinical genome sequencing in patients with hereditary breast and ovarian cancer: Concept, implementation and benefits.

doi:10.1016/j.breast.2025.104505 ·PMID:40403485

Hereditary breast and ovarian cancer (HBOC) is one of the most frequent genetic cancer predisposition syndromes. Individuals at risk are identified mainly by family history and histopathological criteria. The current standard genetic testin…

2023

P259 Immune-mediated implications of SARS-CoV-2 in breast cancer patients

2021

Anti-müllerian hormone levels and antral follicle count in women with a BRCA1 or BRCA2 germline pathogenic variant: A retrospective cohort study.

doi:10.1016/j.breast.2021.07.010 ·PMID:34304065

BackgroundSome studies suggested a decreased ovarian reserve among BRCA1/2 pathogenic variant carriers, with conflicting results.MethodsWe conducted a retrospective single-center observational study of ovarian reserve and spontaneous fertil…

2021

Genetic heterogeneity during breast cancer progression in young patients.

doi:10.1016/j.breast.2021.10.011 ·PMID:34736091

BackgroundBecause a number of years may be required for normal cells to develop into carcinoma, genes involved in tumorigenesis and progression might differ among breast cancers in young women and those in older women. The present study sou…

2021

Ovarian reserve of women with and without BRCA pathogenic variants: A systematic review and meta-analysis.

doi:10.1016/j.breast.2021.09.006 ·PMID:34627117

IntroductionPreliminary clinical evidence suggests a detrimental effect of pathogenic variants of BRCA1 and 2 genes on fertility outcome. This meta-analysis evaluates whether women carrying BRCA mutations (BRCAm) have decreased ovarian rese…